Evidence map›Paper›PMID 33001587›Full record

ReviewWIREs mechanisms of disease2021

Spatiotemporal strategies to identify aggressive biology in precancerous breast biopsies.

David E Frankhauser, Tijana Jovanovic-Talisman, Lily Lai, Lisa D Yee, Lihong V Wang, Ashish Mahabal, Joseph Geradts, Russell C Rockne, Jerneja Tomsic, Veronica Jones and 6 more

Abstract readReview
In one paragraph

Review in WIREs mechanisms of disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. From space to biomedicine: Enabling biomarker data science in the cloud.Cancer biomarkers : section A of Disease markers · 2022
    Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

David E FrankhauserDepartment of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Tijana Jovanovic-TalismanDepartment of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.ORCID 0000-0003-1928-4763
Lily LaiDepartment of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Lisa D YeeDepartment of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Lihong V WangDepartment of Medical Engineering, California Institute of Technology, Pasadena, California, USA.ORCID 0000-0001-9783-4383
Ashish MahabalCenter for Data Driven Discovery, California Institute of Technology, Pasadena, California, USA.
Joseph GeradtsDepartment of Pathology, Duke University, Durham, North Carolina, USA.
Russell C RockneDepartment of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Jerneja TomsicDepartment of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Veronica JonesDepartment of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Christopher SistrunkDepartment of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Gustavo Miranda-CarboniDepartment of Hematology and Oncology, University of Tennessee, Memphis, Memphis, Tennessee, USA.
Eric C DietzeDepartment of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Loretta ErhunmwunseeDepartment of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Terry HyslopDepartment of Biostatistics, Duke University, Durham, North Carolina, USA.
Victoria L SeewaldtDepartment of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California, USA.ORCID 0000-0002-7289-9268

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
Oncology Research Career Development ProgramK12CA001727 · NCI · CITY OF HOPE NATIONAL MEDICAL CENTER · PI MORTIMER, JOANNE E. · 1992 to 2024
$14.6M
Project 2U54CA285116 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI ERNEST MARTINEZ, Victoria L. Seewaldt · 2023 to 2026
$6.8M
Diversity Supplement to Combined Breast MRI/Biomarker Strategies to Identify Aggressive BiologyU01CA189283 · NCI · DUKE UNIVERSITY · PI CLINTON, STEVEN K, MIRANDA-CARBONI, GUSTAVO ADOLFO · 2015 to 2020
$4.0M
Epigenetic damage in women living in LA food-desert zip codesR01CA220693 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI ANN, DAVID K., HYSLOP, TERRY · 2017 to 2021
$3.7M
Tension-Stat3-miR-mediated metastasisR01CA192914 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SEEWALDT, VICTORIA L., WEAVER, VALERIE MARIE · 2015 to 2019
$2.9M
Mechanisms of breast cancer associated with obesityR01CA170851 · NCI · TUFTS UNIVERSITY BOSTON · PI KUPERWASSER, CHARLOTTE, SEEWALDT, VICTORIA L. · 2012 to 2015
$2.6M
Cancer Metabolism Training ProgramT32CA221709 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI David K. Ann, Victoria L. Seewaldt · 2018 to 2026
$1.8M
2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership (Pilot Project 2)P20CA242620 · NCI · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI MARTINEZ, ERNEST, SEEWALDT, VICTORIA L. · 2019 to 2022
$1.2M
Project 2P20CA242619 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI MARTINEZ, ERNEST, SEEWALDT, VICTORIA L. · 2019 to 2022
$937k
NCI NIH HHS K12 CA001727NCI NIH HHS P20 CA242619NCI NIH HHS P20 CA242620NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA170851NCI NIH HHS R01 CA192914NCI NIH HHS R01 CA220693NCI NIH HHS T32 CA221709NCI NIH HHS U01 CA189283NCI NIH HHS U54 CA285116
6 · The paper itself

Abstract

Over 90% of breast cancer is cured; yet there remain highly aggressive breast cancers that develop rapidly and are extremely difficult to treat, much less prevent. Breast cancers that rapidly develop between breast image screening are called "interval cancers." The efforts of our team focus on identifying multiscale integrated strategies to identify biologically aggressive precancerous breast lesions. Our goal is to identify spatiotemporal changes that occur prior to development of interval breast cancers. To accomplish this requires integration of new technology. Our team has the ability to perform single cell in situ transcriptional profiling, noncontrast biological imaging, mathematical analysis, and nanoscale evaluation of receptor organization and signaling. These technological innovations allow us to start to identify multidimensional spatial and temporal relationships that drive the transition from biologically aggressive precancer to biologically aggressive interval breast cancer. This article is categorized under: Cancer > Computational Models Cancer > Molecular and Cellular Physiology Cancer > Genetics/Genomics/Epigenetics.

Indexed as

Breast NeoplasmsPrecancerous ConditionsBiologyBiopsyFemaleHumansMammographybreast imagingearly detectionmultiscale models

Identifiers

PMID33001587
PMCPMC8544796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.